// App-Quantinova.ai

e16029 : Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.

Researchers

Presenter

  • William K. Oh

Principal Investigators

  • Raymond Miao

  • Wendy Y Cheng

  • Daniel Hennessy

  • Marjolaine Gauthier-Loiselle

  • Jonathan Fortier

  • Ravinder Dhawan

  • Mei Sheng Duh

  • Francis Vekeman

  • Jennifer Sung

Medical Centers

  • Analysis Group, Inc., Boston, MA

  • Groupe dAnalyse, Ltee, Montreal, QC, CanadaDivision of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NYSanofi US, Bridgewater, NJ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Alkaline phosphatase

  • Prostate specific antigen

  • Human albumin

Drug/Treatment

  • Alkaline phosphatase

  • Enzalutamide

  • Cabazitaxel

  • CB-7598

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved